论文部分内容阅读
为观察国产天普络欣（尿激酶）在急性脑梗塞静脉溶栓治疗中的疗效和不良反应，并对其疗效和安全性作出评价，我们对３２例急性脑梗塞患者进行了溶栓治疗。所有入选病例均符合入选和不入选标准。一旦病例被选择，立即给予天普络欣尿激酶（ＵＫ），用量从５０万Ｕ至２５０万Ｕ不等。溶栓后观察疗效和副反应，在指定时间观察记录欧洲脑卒中评分及Ｂａｒｔｈｅｌ指数。在３２例病人中，总有效率达９６．９％（其中治愈率８４．４％），梗塞血管再通率高（８７．５％），不良反应发生率低，程度轻。故可认为对急性脑梗塞来说，天普络欣尿激酶是一种安全、高效的静脉溶栓
To observe the curative effect and side effects of domestic-made Pululuoxin (urokinase) in intravenous thrombolytic therapy of acute cerebral infarction and to evaluate its efficacy and safety, we conducted thrombolysis in 32 patients with acute cerebral infarction. All selected cases met the inclusion and non-inclusion criteria. Once the case has been selected, immediately given triprolidine urokinase (UK), the amount from 500,000 U to 2.5 million U range. Efficacy and side effects were observed after thrombolysis. The European Stroke Score and Barthel Index were observed and recorded at the indicated time points. In 32 patients, the total effective rate was 96.9% (84.4% of the cure rate), high rate of recanalization (87.5%), the incidence of adverse reactions, the degree of light. It can be considered for acute cerebral infarction, diphthelin Urokinase is a safe and efficient intravenous thrombolysis